The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
June 21st 2025
Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights
View More
PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies
View More
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
View More
Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma
View More
Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies
View More
Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Belantamab Mafodotin Combos Approach EU Approval for R/R Multiple Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of belantamab mafodotin (Blenrep) in adult patients with relapsed or refractory multiple myeloma.